FB102

FB102 selectively blocks medium affinity IL-2, low affinity IL-15, and medium affinity IL-15/IL-15Rα binding to CD122/CD132 on effector T or NK cells, while sparing high affinity IL-2 binding to Treg CD25/CD122/CD132 receptors, with measured dissociation constants of ~1 nM, ~10 nM, ~0.01 nM, and ~1 nM respectively for each interaction^[1].
FB102 (100 nM) potently inhibits IL-2- and IL-15-induced CD4⁺ and CD8⁺ T cell proliferation by 4.1-fold and 4.6-fold respectively, reducing signaling to unstimulated baseline levels with statistically significant effects^[1].
FB102 (100 nM) potently inhibits IL-2- and IL-15-induced NK cell proliferation by 15.8-fold and 21.8-fold respectively, reducing signaling to unstimulated baseline levels with statistically significant effects^[1].
FB102 does not inhibit IL-2/CD3-induced regulatory T cell proliferation or impact Treg viability in the absence of IL-2 stimulation^[1].
FB102 potently inhibits IL-2- and IL-15-induced secretion of IL-6, TNF-α, IFN-γ, and CSF-1 in T cells from three independent human donors^[1].
FB102 provides nearly complete inhibition of IL-2/IL-15-induced activation of CD4⁺ and CD8⁺ T cells in an in vitro celiac disease model, reducing CD25 expression to near-baseline levels with statistically significant effects^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.